Protagonist Therapeutics, Inc. PTGX announced positive top-line data from the phase IIb ANTHEM-UC study, which evaluated ...

Results from multiple Phase III trials of Icotrokinra in moderate-to-severe plaque psoriasis and a Phase IIb trial in ...

Johnson & Johnson (NYSE:JNJ) said on Monday that its mid-stage study of icotrokinra, for the treatment of moderate to severe ...

Icotrokinra met all primary endpoints in the studies, demonstrating significant skin clearance and clinical remission.

Protagonist Therapeutics, Inc.'s VERIFY and ANTHEM-UC studies show breakthroughs in polycythemia vera and ulcerative colitis.

GlobalData predicts that icotrokinra will reach blockbuster status in 2029, with the drug forecast to generate sales of ...

JNJ's ulcerative colitis drug shows promise in mid-stage trials, with high response rates and well-tolerated safety profile ...

Protagonist Therapeutics (PTGX) announced topline results from ANTHEM-UC, a Phase 2b study of icotrokinra, the first investigational targeted ...

highlighted icotrokinra’s potential to change the treatment landscape for UC, citing its combination of efficacy, tolerability, and convenient once-daily oral dosing. Ulcerative colitis is a ...

Late-stage data also showed that Johnson & Johnson’s icotrokinra was superior to Bristol Myers Squibb’s Sotyktu at clearing ...

H.C. Wainwright raised the firm’s price target on Protagonist Therapeutics (PTGX) to $80 from $54 and keeps a Buy rating on the shares. The ...

On Monday, Protagonist Therapeutics, Inc. PTGX announced topline results from ANTHEM-UC Phase 2b study of icotrokinra ...